1. Antosik-Wójcińska A. Arypiprazol – od wyników badań do zastosowania w praktyce klinicznej. Psychiatr Psychol Klin 2020; 20(1): 66–70. DOI: 10.15557/PiPK.2020.0008.
2.
Bartova L, Dold M, Praschak-Rieder N, Naderi-Heiden A, Kasper S. Intramuscular maintenance treatment with ultra high-dose long-acting injectable aripiprazole in an elderly patient suffering from chronic refractory schizophrenia: A case report. European Psychiatry 2016; 33(S1), S573-S573. DOI: 10.1016/j.eurpsy.2016.01.2120.
3.
Charakterystyka Produktu Leczniczego, Abilify.
4.
Chaumette B, Masson M, Barde M, Gay O, Gaillard R. Relais d’un antipsychotique par l’aripiprazole et risque d’agita tion [Switching from antipsychotics to aripiprazole and risk of agitation]. Encephale 2018; 44(1): 88-90. DOI: 10.1016/j.encep.2017.02.007.
5.
Chavez B, Poveda RA. Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Ann Phar macother 2006; 40(12): 2265–2268. DOI: 10.1345/aph.1H240.
6.
Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS. Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. Basic Clin Pharmacol Toxicol 2018; 122(2): 293–298. DOI: 10.1111/bcpt.12902.
7.
Clarke L, Lindenmayer JP, Kaushik S. Clozapine augumen tation with aripiprazole for negative symptoms, J Clin Psy chiatry 2006; April 67: 4.
8.
Crippa A, Orsini N. Dose-response meta-analysis of differ ences in means. BMC Medical Research Methodology 2016, 16, 91. https://doi.org/10.1186/s12874-016-0189-0.
9.
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs 2015, 29(9), 773–799. https://doi.org/10.1007/s40263-015-0278-3
10.
di Sciascio G, Riva MA. Aripiprazole: from pharmacolog ical profile to clinical use. Neuropsychiatric Disease and Treatment 2015, 11, 2635–2647. https://doi.org/10.2147/NDT.S88117.
11.
Duggal HS, Mendhekar DN. High-dose aripiprazole in treat ment-resistant schizophrenia. J Clin Psychiatry 2006;67(4): 674-675. DOI: 10.4088/jcp.v67n0420c.
12.
Gałecki P, BLiźniewska-Kowalska K. Depresja oporna na le czenie – zalecenia Konsultanta Krajowego w dziedzinie psy chiatrii, Psychiatr. Pol. ONLINE FIRST Nr 158: 1–15, Published ahead of print 30 December 2019, DOI: doi.org/10.12740/PP/OnlineFirst/115208.
13.
Kim E, Howes OD, Kim BH, Jeong JM, Lee JS, Jang IJ, Shin SG, Turkheimer FE, Kapur S, Kwon JS. Predicting brain occupan cy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. Journal of cerebral blood flow and metabo lism: official journal of the International Society of Cerebral Blood Flow and Metabolism 2012; 32(4), 759–768. https://doi.org/10.1038/jcbfm.2011.180.
14.
Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia [published correction appears in Am J Psychiatry 2020 Mar 1; 177(3): 272]. Am J Psychiatry 2020; 177(4): 342–353. DOI: 10.1176/appi.ajp.2019.19010034
15.
Li DJ, Tseng PT, Stubbs B, et al. Efficacy, safety and tol erability of aripiprazole in bipolar disorder: An updat ed systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psy chiatry 2017; 79(Pt B): 289–301. DOI: 10.1016/j.pnpbp.2017.06.023.
16.
Mace S, Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009, 23(9), 773–780. https://doi.org/10.2165/11310820-000000000-00000.
17.
Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Current Pharmaceutical Design 2010, 16(5), 488–501. https://doi.org/10.2174/138161210790361461.
18.
Merk W, Kucia K. Łączne stosowanie zabiegów EW i leków psychotropowych, Psychiatr. Pol. 2015; 49(6): 1241–1253.
19.
Nelson JC, Papakostas GI. Atypical antipsychotic augmen tation in major depressive disorder: a meta-analysis of pla cebo-controlled randomized trials. The American Journal of Psychiatry 2009, 166(9), 980–991. https://doi.org/10.1176/appi.ajp.2009.09030312.
20.
Reszczyński R. Wyższe dawki arypiprazolu – silniejszy efekt antypsychotyczny. Doświadczenia własne w leczeniu ary piprazolem pacjentów chorujących na schizofrenię para noidalną. Psychiatry 2017; 14, 4: 204–208.
21.
Romeo B, Blecha L, Locatelli K, Benyamina A, Martelli C. Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety. J Psychophar macol 2018; 32(4): 385–396. DOI:10.1177/0269881118760661.
22.
Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic re view of aripiprazole – dose, plasma concentration, receptor occupancy and response: Implications for therapeutic drug monitoring. J. Clin. Psychiatry 2010; 71(11): 1447–1456.
23.
Szafrański T. 30 miligramów aripiprazolu. Tylko czy aż. Psychiatria. Pismo dla Praktyków; 2019, z. 4 (27): 60–62.
24.
Thone J. Worsened agitation and confusion in schizophre nia subsequent to high-dose aripiprazole. J Neuropsy chiatry Clin Neurosci 2007; 19(4): 481–482. DOI: 10.1176/jnp.2007.19.4.481.
25.
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA Psychiatry 2019; 76(5): 499–507. DOI: 10.1001/jamapsychiatry.2018.4320.
26.
Urban AE, Cubała WJ. Therapeutic drug monitoring of atyp ical antypsychotics, Psychiatr. Pol. 2017; 51(6): 1059–1077.
27.
Zalecenia konsultanta krajowego w dziedzinie psychiatrii w sprawie stosowania leków przeciwpsychotycznych II ge neracji. Wersja poprawiona: 31.01.2012. Psychiatr. Pol. 2012; 46(2): 313–322.
